CG Oncology Inc. (CGON) had itself a Monday. The company announced positive topline results from its Phase 3 PIVOT-006 trial, and CEO Arthur Kuan did not exactly downplay it, calling the readout a defining milestone for the company.
Kuan said the data position cretostimogene grenadenorepvec as the first and only therapeutic candidate to show a significant recurrence benefit in a pivotal Phase 3 study for intermediate-risk and high-grade Ta NMIBC. That is a mouthful, but it is also the kind of mouthful that gets a biotech company to file for approval. CG Oncology now plans two BLA filings in 2027.
The Numbers Behind The 68%
PIVOT-006 is a registrational study evaluating adjuvant intravesical cretostimogene after complete tumor resection in patients with intermediate-risk and high-grade Ta ≤3 cm NMIBC. For this population of roughly 50,000 patients, there are currently no FDA-approved adjuvant treatments. That is the gap CG Oncology is trying to fill.
The trial met its primary endpoint, delivering statistically significant and clinically meaningful improvements over the control arm. Over a median follow-up of 17 months as of Oct. 26, 2026, cretostimogene reduced recurrence risk by 68% compared with the control arm, achieving a hazard ratio of 0.32.
Patients generally tolerated the drug well, with safety results matching previous studies. The study recorded no Grade 3 or greater treatment-related adverse events and no treatment-related discontinuations. In biotech, a clean safety profile alongside a strong efficacy signal is roughly the equivalent of hitting a serve and landing the volley.
Two Filings, One Broader Strategy
Combined with CG Oncology's existing data in high-risk BCG-unresponsive NMIBC, the PIVOT-006 results could substantially expand the patient populations eligible for cretostimogene if approved.
Kuan noted that the company is working quickly to finish its BLA filing in intermediate-risk and high-grade Ta NMIBC in the second quarter of 2027.
Following FDA feedback, CG Oncology also plans to expand its initial BLA submission in BCG-unresponsive NMIBC. Rather than focusing only on patients with CIS with or without papillary tumors, the submission will include patients with high-grade papillary-only disease to achieve a label reflecting the full range of BCG-unresponsive patients.
To incorporate the extra data, CG Oncology now expects to complete that submission before the end of March 2027. The company has finished all BLA-enabling manufacturing activities supporting both regulatory filings, which is the unglamorous plumbing that has to work before anything gets approved.
What The Market Did
CG Oncology shares were up 16.25% at $86.49 at the time of publication on Monday. The stock is trading at a new 52-week high, according to market data.
That is what a defining milestone looks like on a chart.